2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious

As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is always providing investors with additional reasons to consider buying its stock.On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious about making an investment in it. Here are two new reasons to be in favor of making a purchase, and two yellow flags to consider before doing so.The story of Eli Lilly has, at least recently, been a triumphant one. Thanks to the popularity of its drug for type 2 diabetes, Mounjaro, and that medicine's sibling drug for weight loss, Zepbound, the company's trailing-12-month operating income has risen by 90.7% over the last three years to $15.1 billion. Demand for those products (both versions of the same compound, tirzepatide) has been so high that prior to October, they were in a state of shortage in the U.S.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool